Innate immunity and monocyte-macrophage activation in atherosclerosis

Journal of Inflammation

Volumn 8, Issue , 2011, Pages

  Shalhoub, Joseph ^a   Falck Hansen, Mika A ^a   Davies, Alun H ^a   Monaco, Claudia ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Atherosclerosis; Inflammation; Innate immunity; Macrophage polarisation; Macrophage subtypes; Monocyte subsets; Toll like receptors

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; CD68 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR4; CHOLESTEROL; CXCL11 CHEMOKINE; ENDOTHELIAL CELL GROWTH FACTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INFLAMMASOME; INTERLEUKIN 15 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; INTERLEUKIN 7 RECEPTOR; LIPOPROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; SCATTER FACTOR; SOMATOMEDIN C; T LYMPHOCYTE RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR NRF2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADAPTIVE IMMUNITY; ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CAROTID ENDARTERECTOMY; CELL DIFFERENTIATION; DENDRITIC CELL; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; INNATE IMMUNITY; MACROPHAGE ACTIVATION; MAST CELL; MICROENVIRONMENT; MONOCYTE; NONHUMAN; OXIDATION REDUCTION POTENTIAL; PHENOTYPE; POLARIZATION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TH1 CELL; TH2 CELL;

EID: 79955144904     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/1476-9255-8-9     Document Type: Review

References (196)

1. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. AD Lopez CD Mathers M Ezzati DT Jamison CJ Murray, Lancet 2006 367 9524 1747 57 10.1016/S0140-6736(06)68770-9 16731270 (Pubitemid 43767064)
2. Global Burden of Disease Study Operations Manual. Harvard University, University of Washington, Johns Hopkins University, University of Queensland, World Health Organization 2009
3. Atherosclerosis research from past to present - on the track of two pathologists with opposing views, Carl von Rokitansky and Rudolf Virchow. C Mayerl M Lukasser R Sedivy H Niederegger, Virchows Archiv 2006
4. Atherogenesis and inflammation - was Virchow right? H Methe M Weis, Nephrology Dialysis Transplantation 2007
5. Atherosclerosis - an inflammatory disease. R Ross, N Engl J Med 1999 340 2 115 26 10.1056/NEJM199901143400207 9887164 (Pubitemid 29054847)
6. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. PM Ridker E Danielson FA Fonseca J Genest AM Gotto Jr JJ Kastelein W Koenig P Libby AJ Lorenzatti JG MacFadyen BG Nordestgaard J Shepherd JT Willerson RJ Glynn, N Engl J Med 2008 359 21 2195 207 10.1056/NEJMoa0807646 18997196
7. The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus. L Full C Ruisanchez C Monaco, Arthritis Res Ther 2009 11 2 217 10.1186/ar2631 19435478
8. Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. S Haque H Mirjafari IN Bruce, Curr Opin Lipidol 2008 19 4 338 43 10.1097/MOL.0b013e328304b65f 18607179
9. Atherosclerosis. the road ahead. CK Glass JL Witztum, Cell 2001 104 4 503 16 10.1016/S0092-8674(01)00238-0 11239408
10. Discovery of the role of wall shear in atherosclerosis. CG Caro, Arterioscler Thromb Vasc Biol 2009 29 2 158 61 10.1161/ATVBAHA.108.166736 19038849
11. Atherosclerotic lesion size and vulnerability are determined by patterns of fluid shear stress. C Cheng D Tempel R van Haperen A van der Baan F Grosveld MJ Daemen R Krams R de Crom, Circulation 2006 113 23 2744 53 10.1161/CIRCULATIONAHA.105.590018 16754802 (Pubitemid 43947992)
12. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. MJ Davies PD Richardson N Woolf DR Katz J Mann, Br Heart J 1993 69 5 377 81 10.1136/hrt.69.5.377 8518056 (Pubitemid 23171108)
13. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. AC van der Wal AE Becker CM van der Loos PK Das, Circulation 1994 89 1 36 44 8281670 (Pubitemid 24026469)
14. Pathology of the thin-cap fibroatheroma: a type of vulnerable plaque. R Virmani AP Burke FD Kolodgie A Farb, J Interv Cardiol 2003 16 3 267 72 10.1034/j.1600-0854.2003.8042.x 12800406 (Pubitemid 36667908)
15. CXC chemokine ligand 4 induces a unique transcriptome in monocyte-derived macrophages. CA Gleissner I Shaked KM Little K Ley, J Immunol 2010 184 9 4810 8 10.4049/jimmunol.0901368 20335529
16. Cytokines in atherosclerosis: pathogenic and regulatory pathways. A Tedgui Z Mallat, Physiol Rev 2006 86 2 515 81 10.1152/physrev.00024.2005 16601268
17. A pathobiologic link between risk factors profile and morphological markers of carotid instability. A Mauriello GM Sangiorgi R Virmani S Trimarchi DR Holmes Jr FD Kolodgie DG Piepgras G Piperno D Liotti J Narula P Righini A Ippoliti LG Spagnoli, Atherosclerosis 2010 208 2 572 80 10.1016/j. atherosclerosis.2009.07.048 19683236
18. Lymphotoxin beta receptor signaling promotes tertiary lymphoid organogenesis in the aorta adventitia of aged ApoE-/- mice. R Grabner K Lotzer S Dopping M Hildner D Radke M Beer R Spanbroek B Lippert CA Reardon GS Getz YX Fu T Hehlgans RE Mebius M van der Wall D Kruspe C Englert A Lovas D Hu GJ Randolph F Weih AJ Habenicht, J Exp Med 2009 206 1 233 48 10.1084/jem.20080752 19139167
19. Carotid plaque instability and ischemic symptoms are linked to immaturity of microvessels within plaques. BJ Dunmore MJ McCarthy AR Naylor NP Brindle, J Vasc Surg 2007 45 1 155 9 10.1016/j.jvs.2006.08.072 17210401 (Pubitemid 46038656)
20. The popcorn plaques. J Narula HW Strauss, Nat Med 2007 13 5 532 4 10.1038/nm0507-532 17479093 (Pubitemid 46828471)
21. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. P Duewell H Kono KJ Rayner CM Sirois G Vladimer FG Bauernfeind GS Abela L Franchi G Nunez M Schnurr T Espevik E Lien KA Fitzgerald KL Rock KJ Moore SD Wright V Hornung E Latz, Nature 2010 464 7293 1357 61 10.1038/nature08938 20428172
22. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. YI Miller S Viriyakosol CJ Binder JR Feramisco TN Kirkland JL Witztum, J Biol Chem 2003 278 3 1561 8 10.1074/jbc.M209634200 12424240 (Pubitemid 36801384)
23. Toll-like receptor 4-dependent and -independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages. YI Miller S Viriyakosol DS Worrall A Boullier S Butler JL Witztum, Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 6 1213 9 10.1161/01.ATV.0000159891. 73193.31 15718493 (Pubitemid 40776611)
24. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. CR Stewart LM Stuart K Wilkinson JM van Gils J Deng A Halle KJ Rayner L Boyer R Zhong WA Frazier A Lacy-Hulbert JE Khoury DT Golenbock KJ Moore, Nat Immunol 2010 11 2 155 61 10.1038/ni.1836 20037584
25. The Expression and Functions of Toll-Like Receptors in Atherosclerosis. JE Cole E Georgiou C Monaco, Mediators of Inflammation 2010
26. Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion. JA Van Ginderachter K Movahedi G Hassanzadeh Ghassabeh S Meerschaut A Beschin G Raes P De Baetselier, Immunobiology 2006 211 6-8 487 501 10.1016/j.imbio.2006.06.002 16920488
27. Heterogeneity of human macrophages in culture and in atherosclerotic plaques. SW Waldo Y Li C Buono B Zhao EM Billings J Chang HS Kruth, Am J Pathol 2008 172 4 1112 26 10.2353/ajpath.2008.070513 18321997 (Pubitemid 351520007)
28. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. FO Martinez S Gordon M Locati A Mantovani, J Immunol 2006 177 10 7303 11 17082649 (Pubitemid 44715100)
29. Alternative activation of macrophages. S Gordon, Nat Rev Immunol 2003 3 1 23 35 10.1038/nri978 12511873 (Pubitemid 37328697)
30. The macrophage: past, present and future. S Gordon, Eur J Immunol 2007 37 Suppl 1 9 17 17972350
31. Exploring the full spectrum of macrophage activation. DM Mosser JP Edwards, Nat Rev Immunol 2008 8 12 958 69 10.1038/nri2448 19029990
32. Macrophage diversity and polarization in atherosclerosis: a question of balance. A Mantovani C Garlanda M Locati, Arterioscler Thromb Vasc Biol 2009 29 10 1419 23 10.1161/ATVBAHA.108.180497 19696407
33. Atherosclerosis An immune disease: The Anitschkov Lecture 2007. GK Hansson, Atherosclerosis 2008 1 9
34. The role of adaptive T cell immunity in atherosclerosis. Z Mallat S Taleb H Ait-Oufella A Tedgui, J Lipid Res 2009 50 Suppl 364 9 19050311
35. Macrophage plasticity in experimental atherosclerosis. J Khallou-Laschet A Varthaman G Fornasa C Compain AT Gaston M Clement M Dussiot O Levillain S Graff-Dubois A Nicoletti G Caligiuri, PLoS One 2010 5 1 8852 10.1371/journal.pone.0008852 20111605
36. Identification of a novel macrophage phenotype that develops in response to atherogenic phospholipids via Nrf2. A Kadl AK Meher PR Sharma MY Lee AC Doran SR Johnstone MR Elliott F Gruber J Han W Chen T Kensler KS Ravichandran BE Isakson BR Wamhoff N Leitinger, Circ Res 2010 107 6 737 46 10.1161/CIRCRESAHA. 109.215715 20651288
37. The chemokine system in diverse forms of macrophage activation and polarization. A Mantovani A Sica S Sozzani P Allavena A Vecchi M Locati, Trends Immunol 2004 25 12 677 86 10.1016/j.it.2004.09.015 15530839 (Pubitemid 39457982)
38. IL-33 reduces the development of atherosclerosis. AM Miller D Xu DL Asquith L Denby Y Li N Sattar AH Baker IB McInnes FY Liew, J Exp Med 2008 205 2 339 46 10.1084/jem.20071868 18268038 (Pubitemid 351281600)
39. Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. AM Miller DL Asquith AJ Hueber LA Anderson WM Holmes AN McKenzie D Xu N Sattar IB McInnes FY Liew, Circ Res 2010 107 5 650 8 10.1161/CIRCRESAHA.110.218867 20634488
40. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. MA Bouhlel B Derudas E Rigamonti R Dievart J Brozek S Haulon C Zawadzki B Jude G Torpier N Marx B Staels G Chinetti-Gbaguidi, Cell Metab 2007 6 2 137 43 10.1016/j.cmet.2007.06.010 17681149 (Pubitemid 47189091)
41. Human Atherosclerotic Plaque Alternative Macrophages Display Low Cholesterol Handling but High Phagocytosis Because of Distinct Activities of the PPAR{gamma} and LXRα Pathways. G Chinetti-Gbaguidi M Baron MA Bouhlel J Vanhoutte C Copin Y Sebti B Derudas T Mayi G Bories A Tailleux S Haulon C Zawadzki B Jude B Staels, Circ Res 2011
42. Coronary intraplaque hemorrhage evokes a novel atheroprotective macrophage phenotype. JJ Boyle HA Harrington E Piper K Elderfield J Stark RC Landis DO Haskard, Am J Pathol 2009 174 3 1097 108 10.2353/ajpath.2009.080431 19234137
43. Role of nuclear factor-kappa B activation in metalloproteinase-1, -3, and -9 secretion by human macrophages in vitro and rabbit foam cells produced in vivo. AJ Chase M Bond MF Crook AC Newby, Arterioscler Thromb Vasc Biol 2002 22 5 765 71 10.1161/01.ATV.0000015078.09208.92 12006388 (Pubitemid 34517787)
44. Low tissue inhibitor of metalloproteinases 3 and high matrix metalloproteinase 14 levels defines a subpopulation of highly invasive foam-cell macrophages. JL Johnson GB Sala-Newby Y Ismail CM Aguilera AC Newby, Arterioscler Thromb Vasc Biol 2008 28 9 1647 53 10.1161/ATVBAHA.108.170548 18566294
45. Genomics of foam cells and nonfoamy macrophages from rabbits identifies arginase-I as a differential regulator of nitric oxide production. AC Thomas GB Sala-Newby Y Ismail JL Johnson G Pasterkamp AC Newby, Arterioscler Thromb Vasc Biol 2007 27 3 571 7 10.1161/01.ATV.0000256470.23842.94 17194896
46. Alternative activation of macrophages: mechanism and functions. S Gordon FO Martinez, Immunity 2010 32 5 593 604 10.1016/j.immuni.2010.05.007 20510870
47. Blood monocytes consist of two principal subsets with distinct migratory properties. F Geissmann S Jung DR Littman, Immunity 2003 19 1 71 82 10.1016/S1074-7613(03)00174-2 12871640 (Pubitemid 36859902)
48. Characterization of two novel Ly-6 genes. Protein sequence and potential structural similarity to alpha-bungarotoxin and other neurotoxins. TJ Fleming C O'HUigin TR Malek, J Immunol 1993 150 12 5379 90 8515066 (Pubitemid 23180651)
49. Monocyte subpopulations and their differentiation patterns during infection. D Strauss-Ayali SM Conrad DM Mosser, J Leukoc Biol 2007 82 2 244 52 10.1189/jlb.0307191 17475785 (Pubitemid 47230633)
50. Regulation of the migration and survival of monocyte subsets by chemokine receptors and its relevance to atherosclerosis. EL Gautier C Jakubzick GJ Randolph, Arterioscler Thromb Vasc Biol 2009 29 10 1412 8 10.1161/ATVBAHA.108. 180505 19759373
51. Features of the dendritic cell lineage. RM Steinman J Idoyaga, Immunol Rev 2010 234 1 5 17 10.1111/j.0105-2896.2009.00888.x 20193008
52. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. B Passlick D Flieger HW Ziegler-Heitbrock, Blood 1989 74 7 2527 34 2478233 (Pubitemid 19286475)
53. The novel subset of CD14+/CD16+ blood monocytes exhibits features of tissue macrophages. HW Ziegler-Heitbrock G Fingerle M Strobel W Schraut F Stelter C Schutt B Passlick A Pforte, Eur J Immunol 1993 23 9 2053 8 10.1002/eji.1830230902 7690321 (Pubitemid 23265862)
54. Fractalkine preferentially mediates arrest and migration of CD16+ monocytes. P Ancuta R Rao A Moses A Mehle S Shaw F Luscinskas D Gabuzda, J Exp Med 2003 197 12 1701 7 10.1084/jem.20022156 12810688 (Pubitemid 36745345)
55. Differential chemokine receptor expression and function in human monocyte subpopulations. C Weber KU Belge P von Hundelshausen G Draude B Steppich M Mack M Frankenberger KS Weber HW Ziegler-Heitbrock, J Leukoc Biol 2000 67 5 699 704 10811011
56. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. F Tacke D Alvarez TJ Kaplan C Jakubzick R Spanbroek J Llodra A Garin J Liu M Mack N van Rooijen SA Lira AJ Habenicht GJ Randolph, J Clin Invest 2007 117 1 185 94 10.1172/JCI28549 17200718 (Pubitemid 46048465)
57. Inflammatory chemokine transport and presentation in HEV: a remote control mechanism for monocyte recruitment to lymph nodes in inflamed tissues. RT Palframan S Jung G Cheng W Weninger Y Luo M Dorf DR Littman BJ Rollins H Zweerink A Rot UH von Andrian, J Exp Med 2001 194 9 1361 73 10.1084/jem.194.9. 1361 11696600 (Pubitemid 33055053)
58. Monocyte and macrophage heterogeneity. S Gordon PR Taylor, Nat Rev Immunol 2005 5 12 953 64 10.1038/nri1733 16322748 (Pubitemid 41746764)
59. Comparison of gene expression profiles between human and mouse monocyte subsets. MA Ingersoll R Spanbroek C Lottaz EL Gautier M Frankenberger R Hoffmann R Lang M Haniffa M Collin F Tacke AJ Habenicht L Ziegler-Heitbrock GJ Randolph, Blood 2010 115 3 10 9 10.1182/blood-2009-07-235028 19965649
60. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. F Swirski P Libby E Aikawa P Alcaide F Luscinskas R Weissleder M Pittet, J Clin Invest 2007 117 1 195 205 10.1172/JCI29950 17200719 (Pubitemid 46048466)
61. Heterogeneous in vivo behavior of monocyte subsets in atherosclerosis. FK Swirski R Weissleder MJ Pittet, Arterioscler Thromb Vasc Biol 2009 29 10 1424 32 10.1161/ATVBAHA.108.180521 19372462
62. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. C Auffray MH Sieweke F Geissmann, Annu Rev Immunol 2009 27 669 92 10.1146/annurev.immunol.021908.132557 19132917
63. Unravelling mononuclear phagocyte heterogeneity. F Geissmann S Gordon DA Hume AM Mowat GJ Randolph, Nat Rev Immunol 2010 10 6 453 60 10.1038/nri2784 20467425
64. Development of monocytes, macrophages, and dendritic cells. F Geissmann MG Manz S Jung MH Sieweke M Merad K Ley, Science 2010 327 5966 656 61 10.1126/science.1178331 20133564
65. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. M Nahrendorf FK Swirski E Aikawa L Stangenberg T Wurdinger JL Figueiredo P Libby R Weissleder MJ Pittet, J Exp Med 2007 204 12 3037 47 10.1084/jem.20070885 18025128 (Pubitemid 350179569)
66. Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2-/- mice: evidence for independent chemokine functions in atherogenesis. N Saederup L Chan SA Lira IF Charo, Circulation 2008 117 13 1642 8 10.1161/CIRCULATIONAHA.107.743872 18165355 (Pubitemid 351482604)
67. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. C Combadiere S Potteaux JL Gao B Esposito S Casanova EJ Lee P Debre A Tedgui PM Murphy Z Mallat, Circulation 2003 107 7 1009 16 10.1161/01.CIR.0000057548.68243.42 12600915 (Pubitemid 36258725)
68. Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. P Lesnik CA Haskell IF Charo, J Clin Invest 2003 111 3 333 40 12569158 (Pubitemid 36182209)
69. Major reduction of atherosclerosis in fractalkine (CX3CL1)-deficient mice is at the brachiocephalic artery, not the aortic root. D Teupser S Pavlides M Tan JC Gutierrez-Ramos R Kolbeck JL Breslow, Proc Natl Acad Sci USA 2004 101 51 17795 800 10.1073/pnas.0408096101 15596719 (Pubitemid 40051966)
70. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. L Boring J Gosling M Cleary IF Charo, Nature 1998 394 6696 894 7 10.1038/29788 9732872 (Pubitemid 28410911)
71. Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. TC Dawson WA Kuziel TA Osahar N Maeda, Atherosclerosis 1999 143 1 205 11 10.1016/S0021-9150(98)00318-9 10208497 (Pubitemid 29138720)
72. CCR5 deficiency is not protective in the early stages of atherogenesis in apoE knockout mice. WA Kuziel TC Dawson M Quinones E Garavito G Chenaux SS Ahuja Reddick RL N Maeda, Atherosclerosis 2003 167 1 25 32 10.1016/S0021- 9150(02)00382-9 12618265 (Pubitemid 36255632)
73. Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: involvement of IL-10. A Zernecke EA Liehn JL Gao WA Kuziel PM Murphy C Weber, Blood 2006 107 11 4240 3 10.1182/blood-2005-09-3922 16467202 (Pubitemid 43801346)
74. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. C Combadiere S Potteaux M Rodero T Simon A Pezard B Esposito R Merval A Proudfoot A Tedgui Z Mallat, Circulation 2008 117 13 1649 57 10.1161/CIRCULATIONAHA.107.745091 18347211 (Pubitemid 351482605)
75. Monocyte subset dynamics in human atherosclerosis can be profiled with magnetic nano-sensors. M Wildgruber H Lee A Chudnovskiy TJ Yoon M Etzrodt MJ Pittet M Nahrendorf K Croce P Libby R Weissleder FK Swirski, PLoS One 2009 4 5 5663 10.1371/journal.pone.0005663 19461894
76. CD14+CD16+ monocytes in coronary artery disease and their relationship to serum TNF-alpha levels. A Schlitt GH Heine S Blankenberg C Espinola-Klein JF Dopheide C Bickel KJ Lackner M Iz J Meyer H Darius HJ Rupprecht, Thromb Haemost 2004 92 2 419 24 15269840 (Pubitemid 39172323)
77. Suppression of inflammatory signaling in monocytes from patients with coronary artery disease. SH Schirmer JO Fledderus AM van der Laan TC van der Pouw-Kraan PD Moerland OL Volger JM Baggen M Bohm JJ Piek AJ Horrevoets N van Royen, J Mol Cell Cardiol 2009 46 2 177 85 10.1016/j.yjmcc.2008.10.029 19059264
78. Senescent CD14+CD16+ Monocytes Exhibit Proinflammatory and Proatherosclerotic Activity. A Merino P Buendia A Martin-Malo P Aljama R Ramirez J Carracedo, J Immunol 2011 186 3 1809 15 10.4049/jimmunol.1001866 21191073
79. Human circulating CD14+ monocytes as a source of progenitors that exhibit mesenchymal cell differentiation. M Kuwana Y Okazaki H Kodama K Izumi H Yasuoka Y Ogawa Y Kawakami Y Ikeda, J Leukoc Biol 2003 74 5 833 45 10.1189/jlb.0403170 12960274 (Pubitemid 38040360)
80. Reduced atherosclerosis and inflammatory cytokines in apolipoprotein-E-deficient mice lacking bone marrow-derived interleukin-1alpha. Y Kamari A Shaish S Shemesh E Vax I Grosskopf S Dotan M White E Voronov CA Dinarello RN Apte D Harats, Biochem Biophys Res Commun 2011 405 2 197 203 10.1016/j.bbrc.2011.01.008 21219852
81. Rheumatoid arthritis: opposing actions of haemopoietic growth factors and slow-acting anti-rheumatic drugs. JA Hamilton, Lancet 1993 342 8870 536 9 10.1016/0140-6736(93)91653-4 8102674 (Pubitemid 23259193)
82. Colony-stimulating factors in inflammation and autoimmunity. JA Hamilton, Nat Rev Immunol 2008 8 7 533 44 10.1038/nri2356 18551128 (Pubitemid 351913679)
83. Serial analysis of gene expression in human monocytes and macrophages. S Hashimoto T Suzuki HY Dong N Yamazaki K Matsushima, Blood 1999 94 3 837 44 10419873 (Pubitemid 29361813)
84. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. JD Smith E Trogan M Ginsberg C Grigaux J Tian M Miyata, Proc Natl Acad Sci USA 1995 92 18 8264 8 10.1073/pnas.92.18.8264 7667279
85. CD154-stimulated GM-CSF release by vascular smooth muscle cells elicits monocyte activation - role in atherogenesis. M Stojakovic R Krzesz AH Wagner M Hecker, J Mol Med 2007 85 11 1229 38 10.1007/s00109-007-0225-y 17619839 (Pubitemid 47622220)
86. Granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor exacerbate atherosclerosis in apolipoprotein E-deficient mice. A Haghighat D Weiss MK Whalin DP Cowan WR Taylor, Circulation 2007 115 15 2049 54 10.1161/CIRCULATIONAHA.106.665570 17404156 (Pubitemid 46625956)
87. GM-CSF regulates intimal cell proliferation in nascent atherosclerotic lesions. SN Zhu M Chen J Jongstra-Bilen MI Cybulsky, J Exp Med 2009 206 10 2141 9 10.1084/jem.20090866 19752185
88. Interferon gamma: a master regulator of atherosclerosis. JE McLaren DP Ramji, Cytokine Growth Factor Rev 2009 20 2 125 35 10.1016/j.cytogfr.2008.11.003 19041276
89. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. S Gupta AM Pablo X Jiang N Wang AR Tall C Schindler, J Clin Invest 1997 99 11 2752 61 10.1172/JCI119465 9169506 (Pubitemid 27259823)
90. Reduced transplant arteriosclerosis in murine cardiac allografts placed in interferon-gamma knockout recipients. A Raisanen-Sokolowski T Glysing-Jensen J Koglin ME Russell, Am J Pathol 1998 152 2 359 65 9466561 (Pubitemid 28106381)
91. IL-4 dependent alternatively-activated macrophages have a distinctive in vivo gene expression phenotype. P Loke MG Nair J Parkinson D Guiliano M Blaxter JE Allen, BMC Immunol 2002 3 7 10.1186/1471-2172-3-7 12098359
92. Macrophage death and defective inflammation resolution in atherosclerosis. I Tabas, Nat Rev Immunol 2010 10 1 36 46 19960040
93. Alternatively activated macrophages in helminth infections. T Kreider RM Anthony JF Urban Jr WC Gause, Curr Opin Immunol 2007 19 4 448 53 10.1016/j.coi.2007.07.002 17702561 (Pubitemid 47299196)
94. Immunological alterations induced by polyamine derivatives on murine splenocytes and human mononuclear cells. A Cordeiro-da-Silva J Tavares N Araujo F Cerqueira A Tomas P Kong Thoo Lin A Ouaissi, Int Immunopharmacol 2004 4 4 547 56 10.1016/j.intimp.2004.02.009 15099532 (Pubitemid 38501662)
95. Reversing lipopolysaccharide toxicity by ligating the macrophage Fc gamma receptors. JS Gerber DM Mosser, J Immunol 2001 166 11 6861 8 11359846 (Pubitemid 32467232)
96. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. VA Fadok DL Bratton A Konowal PW Freed JY Westcott PM Henson, J Clin Invest 1998 101 4 890 8 10.1172/JCI1112 9466984 (Pubitemid 28096086)
97. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. EM Sternberg, Nat Rev Immunol 2006 6 4 318 28 10.1038/nri1810 16557263
98. Glucocorticoids promote nonphlogistic phagocytosis of apoptotic leukocytes. Y Liu JM Cousin J Hughes J Van Damme JR Seckl C Haslett I Dransfield J Savill AG Rossi, J Immunol 1999 162 6 3639 46 10092825 (Pubitemid 29313619)
99. The Immunological Basis of Acquired Cellular Resistance. GB Mackaness, J Exp Med 1964 120 105 20 10.1084/jem.120.1.105 14194388
100. Innate immunity, macrophage activation, and atherosclerosis. ZQ Yan GK Hansson, Immunol Rev 2007 219 187 203 10.1111/j.1600-065X.2007.00554.x 17850490 (Pubitemid 47390007)
101. Toll-like receptors and innate immunity. R Medzhitov, Nat Rev Immunol 2001 1 2 135 45 10.1038/35100529 11905821 (Pubitemid 33741967)
102. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. R Medzhitov P Preston-Hurlburt CA Janeway Jr, Nature 1997 388 6640 394 7 10.1038/41131 9237759 (Pubitemid 27334820)
103. The Critical Role of IL-1 Receptor-Associated Kinase 4-Mediated NF-{kappa}B Activation in Modified Low-Density Lipoprotein-Induced Inflammatory Gene Expression and Atherosclerosis. TW Kim M Febbraio P Robinet B Dugar D Greene A Cerny E Latz R Gilmour K Staschke G Chisolm PL Fox PE Dicorleto JD Smith X Li, J Immunol 2011 186 5 2871 80 10.4049/jimmunol.1002242 21278342
104. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. SD Wright RA Ramos PS Tobias RJ Ulevitch JC Mathison, Science 1990 249 4975 1431 3 10.1126/science.1698311 1698311
105. Cross-linking of lipopolysaccharide (LPS) to CD14 on THP-1 cells mediated by LPS-binding protein. PS Tobias K Soldau L Kline JD Lee K Kato TP Martin RJ Ulevitch, J Immunol 1993 150 7 3011 21 7681085 (Pubitemid 23127550)
106. CD36 is a sensor of diacylglycerides. K Hoebe P Georgel S Rutschmann X Du S Mudd K Crozat S Sovath L Shamel T Hartung U Zähringer B Beutler, Nature 2005 433 7025 523 7 10.1038/nature03253 15690042 (Pubitemid 40204309)
107. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. YI Miller SH Choi P Wiesner L Fang R Harkewicz K Hartvigsen A Boullier A Gonen CJ Diehl X Que E Montano PX Shaw S Tsimikas CJ Binder JL Witztum, Circ Res 2011 108 2 235 48 10.1161/CIRCRESAHA.110.223875 21252151
108. An essential role of the NF-kappa B/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. M Li DF Carpio Y Zheng P Bruzzo V Singh F Ouaaz RM Medzhitov AA Beg, J Immunol 2001 166 12 7128 35 11390458 (Pubitemid 32525583)
109. Toll-like receptor 2 mediates apolipoprotein CIII-induced monocyte activation. A Kawakami M Osaka M Aikawa S Uematsu S Akira P Libby K Shimokado FM Sacks M Yoshida, Circ Res 2008 103 12 1402 9 10.1161/CIRCRESAHA.108.178426 18974386
110. Cutting edge: TLR2 is a functional receptor for acute-phase serum amyloid A. N Cheng R He J Tian P Ye R Ye, J Immunol 2008 181 1 22 6 18566366
111. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. S Kim H Takahashi WW Lin P Descargues S Grivennikov Y Kim JL Luo M Karin, Nature 2009 457 7225 102 6 10.1038/nature07623 19122641
112. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. TA Seimon MJ Nadolski X Liao J Magallon M Nguyen NT Feric ML Koschinsky R Harkewicz JL Witztum S Tsimikas D Golenbock KJ Moore I Tabas, Cell Metab 2010 12 5 467 82 10.1016/j.cmet.2010.09.010 21035758
113. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. K Scheibner M Lutz S Boodoo M Fenton J Powell M Horton, J Immunol 2006 177 2 1272 81 16818787 (Pubitemid 44036633)
114. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. L Schaefer A Babelova E Kiss HJ Hausser M Baliova M Krzyzankova G Marsche MF Young D Mihalik M Gotte E Malle RM Schaefer HJ Grone, J Clin Invest 2005 115 8 2223 33 10.1172/JCI23755 16025156 (Pubitemid 41134165)
115. Oxidized low-density lipoprotein correlates positively with toll-like receptor 2 and interferon regulatory factor-1 and inversely with superoxide dismutase-1 expression: studies in hypercholesterolemic swine and THP-1 cells. P Holvoet PC Davey D De Keyzer M Doukouré E Deridder M-L Bochaton-Piallat G Gabbiani E Beaufort K Bishay N Andrieux N Benhabilès G Marguerie, Arterioscler Thromb Vasc Biol 2006 26 7 1558 65 10.1161/01.ATV.0000226553.01555. 02 16690872 (Pubitemid 44288983)
116. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. XH Xu PK Shah E Faure O Equils L Thomas MC Fishbein D Luthringer XP Xu TB Rajavashisth J Yano S Kaul M Arditi, Circulation 2001 104 25 3103 8 10.1161/hc5001.100631 11748108 (Pubitemid 34014065)
117. Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. A Asea M Rehli E Kabingu JA Boch O Bare PE Auron MA Stevenson SK Calderwood, J Biol Chem 2002 277 17 15028 34 10.1074/jbc.M200497200 11836257 (Pubitemid 34952579)
118. Cutting edge: the immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4. L Guillot V Balloy FX McCormack DT Golenbock M Chignard M Si-Tahar, J Immunol 2002 168 12 5989 92 12055204 (Pubitemid 34620010)
119. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. K Midwood S Sacre AM Piccinini J Inglis A Trebaul E Chan S Drexler N Sofat M Kashiwagi G Orend F Brennan B Foxwell, Nat Med 2009 15 7 774 80 10.1038/nm.1987 19561617
120. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. ST Smiley JA King WW Hancock, J Immunol 2001 167 5 2887 94 11509636 (Pubitemid 32768923)
121. The extra domain A of fibronectin activates Toll-like receptor 4. Y Okamura M Watari ES Jerud DW Young ST Ishizaka J Rose JC Chow JF Strauss, J Biol Chem 2001 276 13 10229 33 10.1074/jbc.M100099200 11150311
122. Phenotypic and functional maturation of dendritic cells mediated by heparan sulfate. Y Kodaira SK Nair LE Wrenshall E Gilboa JL Platt, J Immunol 2000 165 3 1599 604 10903769 (Pubitemid 30604597)
123. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. A Biragyn PA Ruffini CA Leifer E Klyushnenkova A Shakhov O Chertov AK Shirakawa JM Farber DM Segal JJ Oppenheim LW Kwak, Science 2002 298 5595 1025 9 10.1126/science.1075565 12411706 (Pubitemid 35247310)
124. From the Cover: Unexpected protective role for Toll-like receptor 3 in the arterial wall. JE Cole TJ Navin AJ Cross ME Goddard L Alexopoulou AT Mitra AH Davies RA Flavell M Feldmann C Monaco, Proc Natl Acad Sci USA 2011 108 6 2372 7 10.1073/pnas.1018515108 21220319
125. mRNA is an endogenous ligand for Toll-like receptor 3. Ni H. J Capodici M Lamphier D Weissman, J Biol Chem 2004 279 13 12542 50 14729660 (Pubitemid 38445825)
126. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. MW Boule C Broughton F Mackay S Akira A Marshak-Rothstein IR Rifkin, J Exp Med 2004 199 12 1631 40 10.1084/jem.20031942 15197227 (Pubitemid 38821996)
127. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. E Leadbetter I Rifkin A Hohlbaum B Beaudette M Shlomchik A Marshak-Rothstein, Nature 2002 416 6881 603 7 10.1038/416603a 11948342 (Pubitemid 34406754)
128. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. CR Stewart LM Stuart K Wilkinson JM van Gils J Deng A Halle KJ Rayner L Boyer R Zhong WA Frazier A Lacy-Hulbert J El Khoury DT Golenbock KJ Moore, Nat Immunol 2010 11 2 155 61 10.1038/ni.1836 20037584
129. Receptors involved in the oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero- 3-phosphorylcholine-mediated synthesis of interleukin-8. A role for Toll-like receptor 4 and a glycosylphosphatidylinositol-anchored protein. KA Walton X Hsieh N Gharavi S Wang G Wang M Yeh AL Cole JA Berliner, J Biol Chem 2003 278 32 29661 6 10.1074/jbc.M300738200 12777373 (Pubitemid 36962351)
130. Specific phospholipid oxidation products inhibit ligand activation of toll-like receptors 4 and 2. KA Walton AL Cole M Yeh G Subbanagounder SR Krutzik RL Modlin RM Lucas J Nakai EJ Smart DK Vora JA Berliner, Arterioscler Thromb Vasc Biol 2003 23 7 1197 203 10.1161/01.ATV.0000079340.80744.B8 12775576 (Pubitemid 36871273)
131. Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: toll-like receptor 4- and spleen tyrosine kinase-dependent activation of NADPH oxidase 2. YS Bae JH Lee SH Choi S Kim F Almazan JL Witztum YI Miller, Circ Res 2009 104 2 210 8 21p following 218 10.1161/CIRCRESAHA.108.181040 19096031
132. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. K Edfeldt J Swedenborg G Hansson Z Yan, Circulation 2002 105 10 1158 61 11889007 (Pubitemid 34225814)
133. Atherosclerotic lesion development and Toll like receptor 2 and 4 responsiveness. A Schoneveld I Hoefer J Sluijter J Laman D de Kleijn G Pasterkamp, Atherosclerosis 2008 197 1 95 104 10.1016/j.atherosclerosis.2007.08. 004 17888930 (Pubitemid 351273277)
134. Increased expression of Toll like receptor 4 on peripheral-blood mononuclear cells in patients with coronary arteriosclerosis disease. H Geng H Lu L Zhang H Zhang L Zhou H Wang R Zhong, Clin Exp Immunol 2006 143 2 269 73 10.1111/j.1365-2249.2005.02982.x 16412050
135. Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. H Methe J Kim S Kofler M Weis M Nabauer J Koglin, Circulation 2005 111 20 2654 61 10.1161/CIRCULATIONAHA.104.498865 15883205 (Pubitemid 40740866)
136. Toll-like receptor 4 expressions on peripheral blood monocytes were enhanced in coronary artery disease even in patients with low C-reactive protein. R Shiraki N Inoue S Kobayashi J Ejiri K Otsui T Honjo M Takahashi K Hirata M Yokoyama S Kawashima, Life Sci 2006 80 1 59 66 10.1016/j.lfs.2006.08. 027 17045300 (Pubitemid 44809296)
137. High expression level of Toll-like receptor 2 on monocytes is an important risk factor for arteriosclerotic disease. S Kuwahata S Fujita K Orihara S Hamasaki R Oba H Hirai K Nagata S Ishida T Kataoka N Oketani H Ichiki Y Iriki K Saihara H Okui Y Ninomiya C Tei, Atherosclerosis 2009
138. Characterization of the expression of TLR2 (toll-like receptor 2) and TLR4 on circulating monocytes in coronary artery disease. K Ashida K Miyazaki E Takayama H Tsujimoto M Ayaori T Yakushiji N Iwamoto A Yonemura K Isoda H Mochizuki H Hiraide M Kusuhara F Ohsuzu, J Atheroscler Thromb 2005 12 1 53 60 15725697
139. Enhanced response of blood monocytes to in vitro lipopolysaccharide- challenge in patients with recurrent unstable angina. G Liuzzo DJ Angiolillo A Buffon V Rizzello C Colizzi F Ginnetti LM Biasucci A Maseri, Circulation 2001 103 18 2236 41 11342470 (Pubitemid 32433711)
140. Monocyte toll-like receptor 2 and 4 responses and expression following percutaneous coronary intervention: association with lesion stenosis and fractional flow reserve. D Versteeg IE Hoefer AH Schoneveld DPV De Kleijn E Busser C Strijder M Emons PR Stella PA Doevendans G Pasterkamp, Heart 2008 94 6 770 776 10.1136/hrt.2007.117259 17686802 (Pubitemid 351744698)
141. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. KS Michelsen MH Wong PK Shah W Zhang J Yano TM Doherty S Akira TB Rajavashisth M Arditi, Proc Natl Acad Sci USA 2004 101 29 10679 84 10.1073/pnas.0403249101 15249654 (Pubitemid 38955802)
142. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. H Bjorkbacka VV Kunjathoor KJ Moore S Koehn CM Ordija MA Lee T Means K Halmen AD Luster DT Golenbock MW Freeman, Nat Med 2004 10 4 416 21 10.1038/nm1008 15034566 (Pubitemid 38508522)
143. Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis. C Monaco SM Gregan TJ Navin BM Foxwell AH Davies M Feldmann, Circulation 2009 120 24 2462 9 10.1161/CIRCULATIONAHA.109.851881 19948979
144. Effects of atherogenic diet consumption on lipoproteins in mouse strains C57BL/6 and C3H. BY Ishida PJ Blanche AV Nichols M Yashar B Paigen, J Lipid Res 1991 32 4 559 68 1856605
145. Atherosclerosis and plasma and liver lipids in nine inbred strains of mice. P Nishina J Wang W Toyofuku F Kuypers B Ishida B Paigen, Lipids 1993 28 7 599 605 10.1007/BF02536053 8355588 (Pubitemid 23207092)
146. Modulation of atherosclerosis in mice by Toll-like receptor 2. AE Mullick PS Tobias LK Curtiss, J Clin Invest 2005 115 11 3149 56 10.1172/JCI25482 16211093 (Pubitemid 41567579)
147. Toll-like receptor-2 mediates diet and/or pathogen associated atherosclerosis: proteomic findings. M Madan S Amar, PLoS ONE 2008 3 9 3204 10.1371/journal.pone.0003204 18787704
148. Toll-like receptor 2 plays a critical role in the progression of atherosclerosis that is independent of dietary lipids. X Liu T Ukai H Yumoto M Davey S Goswami FC Gibson CA Genco, Atherosclerosis 2008 196 1 146 54 10.1016/j.atherosclerosis.2007.03.025 17466307
149. In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions. A Vink AH Schoneveld JJ van der Meer BJ van Middelaar JP Sluijter MB Smeets PH Quax SK Lim C Borst G Pasterkamp DP de Kleijn, Circulation 2002 106 15 1985 90 10.1161/01.CIR.0000032146.75113.EE 12370224 (Pubitemid 35176306)
150. Toll-like receptor 2 stimulation induces intimal hyperplasia and atherosclerotic lesion development. AH Schoneveld MM Oude Nijhuis B van Middelaar JD Laman DP de Kleijn G Pasterkamp, Cardiovasc Res 2005 66 1 162 9 10.1016/j.cardiores.2004.12.016 15769459 (Pubitemid 40357879)
151. Local overexpression of toll-like receptors at the vessel wall induces atherosclerotic lesion formation: synergism of TLR2 and TLR4. M Shinohara K Hirata T Yamashita T Takaya N Sasaki R Shiraki T Ueyama N Emoto N Inoue M Yokoyama S Kawashima, Arterioscler Thromb Vasc Biol 2007 27 11 2384 91 10.1161/ATVBAHA.106.139253 17872459 (Pubitemid 350203954)
152. Determinants of atherosclerosis susceptibility in the C3H and C57BL/6 mouse model: evidence for involvement of endothelial cells but not blood cells or cholesterol metabolism. W Shi NJ Wang DM Shih VZ Sun X Wang AJ Lusis, Circ Res 2000 86 10 1078 84 10827138 (Pubitemid 30367867)
153. Lipopolysaccharide stimulation of RAW 264.7 macrophages induces lipid accumulation and foam cell formation. J Funk K Feingold A Moser C Grunfeld, Atherosclerosis 1993 98 1 67 82 10.1016/0021-9150(93)90224-I 8457252 (Pubitemid 23010425)
154. A combination of Lox-1 and Nox1 regulates TLR9-mediated foam cell formation. JG Lee EJ Lim DW Park SH Lee JR Kim SH Baek, Cell Signal 2008 20 12 2266 75 10.1016/j.cellsig.2008.08.022 18817866
155. Increased susceptibility to activation and increased uptake of low density lipoprotein by cholesterol-loaded macrophages. J Oiknine M Aviram, Arterioscler Thromb 1992 12 6 745 53 1591234
156. Lipoprotein accumulation in macrophages via toll-like receptor-4-dependent fluid phase uptake. Choi S R Harkewicz J Lee A Boullier F Almazan A Li J Witztum Y Bae Y Miller, Circ Res 2009 104 12 1355 63 10.1161/CIRCRESAHA.108.192880 19461045
157. Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. A Bar-Or RK Nuttall M Duddy A Alter HJ Kim I Ifergan CJ Pennington P Bourgoin DR Edwards VW Yong, Brain 2003 126 Pt 12 2738 49 14506071 (Pubitemid 37463092)
158. Neutral metalloproteinases produced by human mononuclear phagocytes. Enzyme profile, regulation, and expression during cellular development. HG Welgus EJ Campbell JD Cury AZ Eisen RM Senior SM Wilhelm GI Goldberg, J Clin Invest 1990 86 5 1496 502 10.1172/JCI114867 2173721 (Pubitemid 20372596)
159. Oxidized low-density and high-density lipoproteins regulate the production of matrix metalloproteinase-1 and -9 by activated monocytes. JA Ardans AP Economou JM Martinson Jr M Zhou LM Wahl, J Leukoc Biol 2002 71 6 1012 8 12050187
160. TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages. P Saren HG Welgus PT Kovanen, J Immunol 1996 157 9 4159 65 8892653 (Pubitemid 126449330)
161. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. MP Herman GK Sukhova P Libby N Gerdes N Tang DB Horton M Kilbride RE Breitbart M Chun U Schonbeck, Circulation 2001 104 16 1899 904 10.1161/hc4101.097419 11602491 (Pubitemid 32983231)
162. Immune modulation of metalloproteinase production in human macrophages. Selective pretranslational suppression of interstitial collagenase and stromelysin biosynthesis by interferon-gamma. SD Shapiro EJ Campbell DK Kobayashi HG Welgus, J Clin Invest 1990 86 4 1204 10 10.1172/JCI114826 2170447 (Pubitemid 20370426)
163. Expression of tissue inhibitor of metalloproteinases-3 in human atheroma and regulation in lesion-associated cells: a potential protective mechanism in plaque stability. RP Fabunmi GK Sukhova S Sugiyama P Libby, Circ Res 1998 83 3 270 8 9710119 (Pubitemid 28371316)
164. Type I interferon inhibits interleukin-1 production and inflammasome activation. G Guarda M Braun F Staehli A Tardivel C Mattmann I Forster M Farlik T Decker RA Du Pasquier P Romero J Tschopp, Immunity 2011 34 2 213 23 10.1016/j.immuni.2011.02.006 21349431
165. Interferon-beta attenuates angiotensin II-accelerated atherosclerosis and vascular remodeling in apolipoprotein E deficient mice. LN Zhang S Velichko J Vincelette RM Fitch R Vergona ME Sullivan E Croze YX Wang, Atherosclerosis 2008 197 1 204 11 10.1016/j.atherosclerosis.2007.03.019 17466308 (Pubitemid 351273239)
166. Myeloid type I interferon signaling promotes atherosclerosis by stimulating macrophage recruitment to lesions. P Goossens MJ Gijbels A Zernecke W Eijgelaar MN Vergouwe I van der Made J Vanderlocht L Beckers WA Buurman MJ Daemen U Kalinke C Weber E Lutgens MP de Winther, Cell Metab 2010 12 2 142 53 10.1016/j.cmet.2010.06.008 20674859
167. Activation of Endothelial Toll-Like Receptor 3 Impairs Endothelial Function. S Zimmer M Steinmetz T Asdonk I Motz C Coch E Hartmann W Barchet S Wassmann G Hartmann G Nickenig, Circ Res 2011
168. Blockade of the interaction between PD-1 and PD-L1 accelerates graft arterial disease in cardiac allografts. N Koga J Suzuki H Kosuge G Haraguchi Y Onai H Futamatsu Y Maejima R Gotoh H Saiki F Tsushima M Azuma M Isobe, Arterioscler Thromb Vasc Biol 2004 24 11 2057 62 10.1161/01.ATV.0000145015. 23656.e4 15374847 (Pubitemid 39482430)
169. TLR-mediated induction of negative regulatory ligands on dendritic cells. S Groschel KD Piggott A Vaglio W Ma-Krupa K Singh JJ Goronzy CM Weyand, J Mol Med 2008 86 4 443 55 10.1007/s00109-008-0310-x 18253710
170. The microtubule regulator stathmin is an endogenous protein agonist for TLR3. M Bsibsi JJ Bajramovic MH Vogt E van Duijvenvoorden A Baghat C Persoon-Deen F Tielen R Verbeek I Huitinga B Ryffel A Kros WH Gerritsen S Amor JM van Noort, J Immunol 2010 184 12 6929 37 10.4049/jimmunol.0902419 20483774
171. The inflammasomes: guardians of the body. F Martinon A Mayor J Tschopp, Annu Rev Immunol 2009 27 229 65 10.1146/annurev.immunol.021908.132715 19302040
172. Murine caspase-11, an ICE-interacting protease, is essential for the activation of ICE. S Wang M Miura YK Jung H Zhu E Li J Yuan, Cell 1998 92 4 501 9 10.1016/S0092-8674(00)80943-5 9491891 (Pubitemid 28101113)
173. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. S Mariathasan DM Monack, Nat Rev Immunol 2007 7 1 31 40 10.1038/nri1997 17186029 (Pubitemid 46020825)
174. New insights into the mechanism of IL-1beta maturation. K Burns F Martinon J Tschopp, Curr Opin Immunol 2003 15 1 26 30 10.1016/S0952-7915(02) 00017-1 12495729 (Pubitemid 35454188)
175. Critical role of bone marrow apoptosis-associated speck-like protein, an inflammasome adaptor molecule, in neointimal formation after vascular injury in mice. N Yajima M Takahashi H Morimoto Y Shiba Y Takahashi J Masumoto H Ise J Sagara J Nakayama S Taniguchi U Ikeda, Circulation 2008 117 24 3079 87 10.1161/CIRCULATIONAHA.107.746453 18541743
176. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. H Kirii T Niwa Y Yamada H Wada K Saito Y Iwakura M Asano H Moriwaki M Seishima, Arterioscler Thromb Vasc Biol 2003 23 4 656 60 10.1161/01.ATV.0000064374.15232.C3 12615675 (Pubitemid 36438080)
177. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. R Elhage J Jawien M Rudling HG Ljunggren K Takeda S Akira F Bayard GK Hansson, Cardiovasc Res 2003 59 1 234 40 10.1016/S0008-6363(03)00343-2 12829194 (Pubitemid 36776389)
178. Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size. CM Devlin G Kuriakose E Hirsch I Tabas, Proc Natl Acad Sci USA 2002 99 9 6280 5 10.1073/pnas.092324399 11983917 (Pubitemid 34493303)
179. Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis. R Dewberry H Holden D Crossman S Francis, Arterioscler Thromb Vasc Biol 2000 20 11 2394 400 11073843
180. Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice. N Ishii T Matsumura H Kinoshita K Fukuda H Motoshima T Senokuchi S Nakao A Tsutsumi S Kim-Mitsuyama T Kawada M Takeya N Miyamura T Nishikawa E Araki, Arterioscler Thromb Vasc Biol 2010 30 8 1598 605 10.1161/ATVBAHA.109.202309 20508203
181. Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARgamma ligand pioglitazone. H Nakaya BD Summers AC Nicholson AM Gotto Jr DP Hajjar J Han, Am J Pathol 2009 174 6 2007 14 10.2353/ajpath.2009.080611 19435790
182. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. G Chinetti JC Fruchart B Staels, Inflamm Res 2000 49 10 497 505 10.1007/s000110050622 11089900
183. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. JI Odegaard RR Ricardo-Gonzalez MH Goforth CR Morel V Subramanian L Mukundan A Red Eagle D Vats F Brombacher AW Ferrante A Chawla, Nature 2007 447 7148 1116 20 10.1038/nature05894 17515919 (Pubitemid 47014427)
184. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. P Tontonoz L Nagy JG Alvarez VA Thomazy RM Evans, Cell 1998 93 2 241 52 10.1016/S0092-8674(00)81575-5 9568716 (Pubitemid 28180857)
185. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. DS Straus CK Glass, Trends Immunol 2007 28 12 551 8 10.1016/j.it.2007.09.003 17981503 (Pubitemid 350101420)
186. Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. LK Heilbronn LV Campbell, Curr Pharm Des 2008 14 12 1225 30 10.2174/138161208784246153 18473870 (Pubitemid 351997835)
187. PPARgamma promotes mannose receptor gene expression in murine macrophages and contributes to the induction of this receptor by IL-13. A Coste M Dubourdeau MD Linas S Cassaing JC Lepert P Balard S Chalmeton J Bernad C Orfila JP Seguela B Pipy, Immunity 2003 19 3 329 39 10.1016/S1074-7613(03)00229-2 14499109 (Pubitemid 37153410)
188. Involvement of IL-10 in peroxisome proliferator-activated receptor gamma-mediated anti-inflammatory response in asthma. SR Kim KS Lee HS Park SJ Park KH Min SM Jin YC Lee, Mol Pharmacol 2005 68 6 1568 75 16150927
189. Inhibition of MMP-9 expression by PPARgamma activators in human bronchial epithelial cells. M Hetzel D Walcher M Grub H Bach V Hombach N Marx, Thorax 2003 58 9 778 83 10.1136/thorax.58.9.778 12947137 (Pubitemid 37094054)
190. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. N Marx A Imhof J Froehlich L Siam J Ittner G Wierse A Schmidt W Maerz V Hombach W Koenig, Circulation 2003 107 15 1954 7 10.1161/01.CIR.0000069272.06194.91 12695287 (Pubitemid 36506065)
191. Peroxisome-proliferator-activated receptors gamma and peroxisome-proliferator-activated receptors beta/delta and the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischaemic brain. T Glatz I Stock M Nguyen-Ngoc P Gohlke T Herdegen J Culman Y Zhao, J Hypertens 2010 28 7 1488 97 10.1097/HJH.0b013e3283396e4e 20410836
192. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism. D Moulin A Bianchi S Boyault S Sebillaud M Koufany M Francois P Netter JY Jouzeau B Terlain, Arthritis Rheum 2005 52 3 759 69 10.1002/art.20868 15751073 (Pubitemid 40365097)
193. Treatment with the PPARgamma agonist rosiglitazone downregulates interleukin-1 receptor antagonist in individuals with metabolic syndrome. B Halvorsen E Heggen T Ueland C Smith WJ Sandberg JK Damas K Otterdal S Tonstad P Aukrust, Eur J Endocrinol 2010 162 2 267 73 10.1530/EJE-09-0706 19926782
194. Peroxisome proliferator-activated receptors in the modulation of the immune/inflammatory response in atherosclerosis. AZ Fernandez, PPAR Res 2008 2008 285842 18769491
195. The CD14+ CD16+ blood monocytes: their role in infection and inflammation. L Ziegler-Heitbrock, J Leukoc Biol 2007 81 3 584 92 17135573 (Pubitemid 46393535)
196. Monocytes: subsets, origins, fates and functions. S Yona S Jung, Curr Opin Hematol 2010 17 1 53 9 10.1097/MOH.0b013e3283324f80 19770654